Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ICCC vs IRIX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ICCC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–1 Matrix Metrics)
ICCC Overall Winner
6-Pillar Tally: ICCC 3 – 2 IRIX (1 Tie)
Matrix Metrics: ICCC 8 – 1 IRIX
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Iridex Corp (IRIX) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas IRIX carries 51.8/100 (HOLD) at $0.69 (N/M Forward P/E, -5.4% operating margin).
- Composite vs. Pillar Nuance: While IRIX currently prints a higher short-term Unified Composite Score (51.8/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (8–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (15.2% vs. -5.4% operating margin) and revenue trajectory (+11.5% vs. -7.4% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ICCC vs IRIX
ICCC
Head-to-Head Winner
Immucell Corp
$11.42
+6.23% 1D
Market Cap
$97.7M
TTM Revenue
$67M
Forward P/E
N/M
Beta / 30D Vol
0.24β · 46% Vol
Unified Composite Score
43.8
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
IRIX
Iridex Corp
$0.69
-0.32% 1D
Market Cap
$12.1M
TTM Revenue
$52M
Forward P/E
N/M
Beta / 30D Vol
0.66β · 58% Vol
Unified Composite Score
51.8
HOLD
Tech 52.0
Fund 65.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (ICCC 3 – 2 IRIX)
1. Valuation Multiples
IRIX
Forward P/E
N/M
N/M
Trailing P/E
56.6x
N/M
PEG Ratio
N/M
0.94x
EV / Revenue
1.6x
0.2x
2. Growth & Scale
ICCC
Revenue Growth (YoY)
+11.5%
-7.4%
Earnings Growth (YoY)
+259.9%
+0.0%
TTM Revenue (USD)
$67M
$52M
Market Cap
$97.7M
$12.1M
3. Profitability & Quality
ICCC
Gross Margin
40.3%
35.9%
Operating Margin
15.2%
-5.4%
Net Profit Margin
2.6%
-6.9%
Return on Equity (ROE)
2.6%
-73.2%
4. Balance Sheet & Cash Flow
ICCC
Cash Generation (TTM)
$7.4M
-$2.5M
Cash Flow Margin
11.0%
-4.9%
Net Cash / Leverage
$13M Net Debt (0.44x D/E)
-$319,000 Net Debt (0.90x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
IRIX
OpEx & R&D Intensity
25.1% of Rev ($17M)
41.3% of Rev ($21M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ICCC (8) vs IRIX (1)| Institutional Metric | ICCC | IRIX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $97.7M | $12.1M | ICCC | |
| Trailing P/E Ratio | 56.6x | N/M | ICCC | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +11.5% | -7.4% | ICCC | |
| Operating Margin (TTM) | 15.2% | -5.4% | ICCC | |
| Net Profit Margin | 2.6% | -6.9% | ICCC | |
| Return on Equity (ROE) | 2.6% | -73.2% | ICCC | |
| 52-Week Range Position | 91% ($5–$12) | 8% ($1–$2) | ICCC | |
| Beta / 30D Volatility | 0.24β · 46% Vol | 0.66β · 58% Vol | ICCC | |
| Unified Institutional Score | 43.8 / 100 (HOLD) | 51.8 / 100 (HOLD) | IRIX | |
| Trailing 12M Revenue (USD) | $67M | $52M | Scale | |
| Gross Profit Margin (TTM) | 40.3% | 35.9% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.6x EV/Rev | 0.94x PEG · 0.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $7.4M ($13M Net Debt (0.44x D/E)) | -$2.5M (-$319,000 Net Debt (0.90x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ICCC +21.8 pp
3M Horizon
ICCC +43.06 pp
6M Horizon
ICCC +47.48 pp
1Y Horizon
ICCC +111.25 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ICCC Revenue | IRIX Revenue | ICCC Op. Margin | IRIX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $40M | -7.0% | -20.7% | ICCC |
| FY2020 | $20M | N/A | -9.0% | N/A | ICCC |
| FY2021 | $20M | $40M | 1.3% | -18.1% | ICCC |
| FY2022 | $20M | $60M | -12.4% | -13.2% | ICCC |
| FY2023 | $20M | $50M | -32.9% | -19.3% | IRIX |
| FY2024 | $30M | $50M | -6.2% | -17.1% | ICCC |
| FY2025 | $30M | N/A | 6.0% | N/A | ICCC |
| FY2026 | N/A | $50M | N/A | -4.9% | IRIX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ICCC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ICCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
IRIX
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact IRIX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ICCC Moat Profile
Scale & Operating Efficiency Moat
Biotechnology Operator
OpEx & R&D Reinvestment
25.1% of Rev ($17M)
90D Engineering Disclosures
0 Published
IRIX Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
41.3% of Rev ($21M)
90D Engineering Disclosures
0 Published
Investor FAQ ICCC vs IRIX Key Questions & Quantitative Answers
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Iridex Corp (IRIX) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas IRIX carries 51.8/100 (HOLD) at $0.69 (N/M Forward P/E, -5.4% operating margin). Composite vs. Pillar Nuance: While IRIX currently prints a higher short-term Unified Composite Score (51.8/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (8–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (15.2% vs. -5.4% operating margin) and revenue trajectory (+11.5% vs. -7.4% YoY).
ICCC leads the Growth & Scale pillar: ICCC posts +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin), compared with IRIX at -7.4% YoY revenue growth and +0.0% YoY earnings growth on $52M TTM revenue (35.9% gross margin, -5.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), ICCC cumulative revenue shifted +200.0% while IRIX shifted +25.0%. In operating R&D and SG&A reinvestment, ICCC deploys 25.1% of Rev ($17M) (0 90-day corporate R&D disclosures) versus 41.3% of Rev ($21M) (0 disclosures) for IRIX.
IRIX screens cheaper on headline valuation multiples. ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin), whereas IRIX trades at N/M Forward P/E, N/M Trailing P/E, 0.94x PEG, and 0.2x EV/Revenue (-4.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICCC (2.6% ROE) versus IRIX (-73.2% ROE) capital efficiency.
In options market volatility and institutional positioning, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk). By comparison, IRIX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
IRIX vs ICCC · Reverse Pair
ICCC vs CSBR
· Sector Peer
ICCC vs INTG
· Sector Peer
IRIX vs FOCL
· Sector Peer
IRIX vs CPIX
· Sector Peer
IRIX vs INFU
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem